Vanderbilt Vaccine Center

Tesha Akins
August 10, 2021

Shared antibodies may push COVID-19 variants: VUMC study

Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.

By Bill Snyder
July 16, 2021

Study identifies monoclonal antibodies that may neutralize many norovirus variants

Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

By Bill Snyder
June 22, 2021

Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.

By Bill Snyder
May 24, 2021

Therapeutic antibodies for hantavirus

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.

By Bill Snyder
April 12, 2021

VUMC team’s COVID-19 research featured on “60 Minutes”

James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”

By Bill Snyder
James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
April 12, 2021

Crowe receives SEC Faculty Achievement Award

James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.

By VUMC News and Communications
April 6, 2021

U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
By Bill Snyder
April 1, 2021

Novel way to neutralize Rift Valley Fever Virus

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
By Bill Snyder
April 1, 2021

Study shows new COVID target could improve vaccines

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
By Bill Snyder
March 4, 2021

Monoclonal antibody “cocktail” blocks COVID-19 variants: study

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
By Bill Snyder
March 4, 2021

Chikungunya antibody identified at VUMC moves forward

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
By Bill Snyder
February 11, 2021

Carells to endow chair in Pediatric Infectious Diseases

Julie Carell Stadler, Kathryn Carell Brown and Edie Carell Johnson have made a commitment to endow a new chair in Pediatric Infectious Diseases research at Vanderbilt University School of Medicine. The inaugural chair holder of the Edie Carell Johnson Chair in Pediatrics will be announced this spring.
By Nancy Humphrey
December 10, 2020

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
By Bill Snyder
1 2 3 4 5 6 … 14